October 25, 2016

Mitsubishi Tanabe Pharma Corporation
Revision to Consolidated Financial Forecasts
for Fiscal Year Ending March 31, 2017

Osaka, Japan, October 25, 2016 --- Mitsubishi Tanabe Pharma Corporation (Head office: Chuo-ku, Osaka,President and Representative Director: Masayuki Mitsuka) announced today a revision to the 2Q andfull-year consolidated financial forecasts for the fiscal year 2016 ending March 31, 2017, which wereannounced on May 11, 2016.

1.

Revised consolidated financial forecasts for 2Q (April 1, 2016 to September 30, 2016) (Millions of Yen)

RevenueOperatingprofit

Profit beforetax

Net profit for theperiod

Net profit
attributable toowners of theCompanyNet profit
per share(Yen)Previous forecast (A)193,000

38,00038,50027,10028,50050.80

Revised forecast (B)204,000

47,50049,00035,00036,00064.17

11,0009,500

10,500

7,900

7,500

－

5.7

25.0

27.3

29.2

26.3

－

202,065

49,28449,70334,71935,71363.66

Difference (B-A)
Percentage change (%)(Reference)FY2015 2Q(results, cumulative)

Core operating profit* 2Q (cumulative forecast, Millions of Yen): ¥38,000 (previous) ¥47,500 (current)”Core operating profit” is the one that excludes our defined non-recurring income and loss from operating
profit.

We set it up as indicating recurring profitability when IFRS was installed.

FY2015 was also basedon IFRS.

2.

Revised consolidated financial forecasts for FY2016 (April 1, 2016 to March 31, 2017) (Millions of Yen)

Revenue

OperatingprofitProfit beforetax

Net profit for theperiod

Net profit
attributable toowners of theCompany

Net profit
per share(Yen)Previous forecast (A)406,500

75,50077,00054,20057,000101.61

Revised forecast (B)414,000

84,00086,00062,00064,000114.08

7,500

8,500

9,000

7,800

7,000

－

1.8

11.3

11.7

14.4

12.3

－

425,764

81,803

83,25557,03459,306105.72Difference (B-A)
Percentage change (%)(Reference)FY2015 4Q(results, cumulative)

Core operating profit FY2016(cumulative forecast, Millions of Yen): ¥77,000 (previous)¥85,000 (current)

3.

Reasons for revision:
In cumulative 2Q, we expect that sales revenue surpasses the level of the previously announced forecast

due to favorable domestic sales of main products; Simponi, and vaccines, etc.
In profits, addition to the reason above, decline of expenses due to SG&A and R&D expenses deferredand effect of appreciation of JPY, we estimate that all levels of profits under the operating profit surpass thepreviously announced forecasts.
In regard to the full-year forecast, we anticipate decrease in oversea royalty income due to appreciationof JPY and favorable sales of main products; Simponi, and vaccines, etc. The total sales are expected tosurpass the previously announced forecast.
In profits, addition to the reason above, a part of R&D expenses will be incurred in the next fiscal year andbe declined by the appreciation of JPY.

We estimate that all level of profits under the operating profit

surpass those we disclosed earlier.
Note: The above results forecasts reflect judgments and assumptions that are based on information
available at the present point in time. For any of a number of reasons, actual results might differ materiallyfrom these forecasts.

End